Skip to main content

Table 2 Baseline Characteristics

From: The evolution of mean arterial pressure in critically ill patients on vasopressors before and during a trial comparing a specific mean arterial pressure target to usual care

Characteristic

Usual care before vs. during the trial

Usual care pre-trial vs. non-enrolled vs. usual care controls

Pre-trial period

(N = 200)

During-trial period (N = 229)

Pre-trial group (N = 200)

Non-enrolled group (N = 155)

Usual care control group (N = 74)

Age, years (mean [SD])

74.5 (7.2)

75.2 (6.9)

74.5 (7.2)

75.1 (6.8)

75.4 (7.2)

Males (n - %)

110 (55)

148 (64.6)

110 (55)

101 (65.2)

47 (63.5)

APACHE II score (median [IQR])

26 (20–31)

26 (21–31)

26 (20–31)

27 (22–31)

25.5 (20–29)

Comorbidities (n [%])

Cardiac

  Supraventricular arrhythmia

48 (24)

66 (28.8)

48 (24)

47 (30.3)

19 (25.7)

  Ventricular arrhythmia

0 (0)

3 (1.3)

0 (0)

3 (1.9)

0 (0)

  Angina, MI, previous PCI, or CABG

51 (25.5)

63 (27.5)

51 (25.5)

55 (35.5)

8 (10.8)

  CHF class I-III

24 (12.1)

42 (18.3)

24 (12.1)

32 (20.7)

10 (13.5)

  CHF class IV

3 (1.5)

5 (2.2)

3 (1.5)

0 (0)

5 (6.8)

Vascular

  Chronic hypertension

126 (63)

153 (66.8)

126 (63)

102 (65.8)

51 (68.9)

  Peripheral vascular disease or claudication

37 (18.5)

29 (12.7)

37 (18.5)

23 (14.8)

6 (8.1)

  Cerebrovascular disease

19 (9.5)

40 (17.5)

19 (9.5)

22 (14.2)

18 (24.3)

Endocrine

  Diabetes

75 (37.5)

87 (38)

75 (37.5)

57 (36.8)

30 (40.5)

Renal

  Chronic dialysis

15 (7.5)

9 (3.9)

15 (7.5)

4 (2.6)

5 (6.8)

Gastrointestinal

  Moderate to severe liver disease

7 (3.5)

9 (3.9)

7 (3.5)

6 (3.9)

3 (4.1)

Respiratory

  Chronic lung disease

54 (27)

66 (28.8)

54 (27)

50 (32.3)

16 (21.6)

Immunosuppression

  Chemotherapy or chronic immunosuppressive

42 (21)

35 (15.3)

42 (21)

28 (18.1)

7 (9.5)

  medications or transplantation

     

Neurologic

  Cognitive impairment

16 (8)

16 (7)

16 (8.0)

14 (9)

2(2.7)

Reason for ICU Admission (n [%])

Medical

  Cardiovascular/Vascular

3 (0.7)

10 (2.3)

3 (0.7)

9 (2.1)

1 (0.2)

  Respiratory

38 (8.9)

52 (12.1)

38 (8.9)

40 (9.3)

12 (2.8)

  Gastrointestinal

11 (2.6)

13 (3.0)

11 (2.6)

8 (1.9)

5 (1.2)

  Sepsis

99 (23.1)

101 (23.5)

99 (23.1)

64 (14.9)

37 (8.6)

  Other

8 (1.9)

8 (1.9)

8 (1.9)

3 (0.7)

5 (1.2)

Surgical

  Cardiovascular/vascular

4 (0.9)

3 (0.7)

4 (0.9)

3 (0.7)

0 (0)

  Respiratory

14 (3.3)

6 (1.4)

14 (3.3)

6 (1.4)

0 (0)

  Gastrointestinal

19 (4.4)

30 (7.0)

19 (4.4)

18 (4.2)

12 (2.8)

  Other

4 (0.9)

6 (1.4)

4 (0.9)

4 (0.9)

2 (0.5)

Life support at baseline (n [%])

 Invasive ventilation

102 (51.0)

144 (62.9)

102 (51.0)

95 (61.3)

49 (66.2)

 Non-invasive ventilation

75 (37.5)

50 (21.8)

75 (37.5)

33 (21.3)

17 (23)

 Renal replacement therapy

17 (8.5)

10 (4.4)

17 (8.5)

6 (3.9)

4 (5.4)

MAP at inclusion, mmHg (mean [SD])

68.2 (13.7)

70 (13.1)

68.2 (13.7)

68.9 (14.4)

72.2 (9.7)

Vasopressor dose-rate at inclusion, ug/kg/min (mean [SD])

0.15 (0.23)

0.15 (0.18)

0.15 (0.23)

0.13 (0.17)

0.19 (0.19)

  1. Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II score, CABG coronary artery bypass grafting, CHF congestive heart failure, ICU intensive care unit, IQR interquartile range, MAP mean arterial pressure, MI myocardial infarction, PCI percutaneous coronary intervention, SD standard deviation